These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
441 related articles for article (PubMed ID: 29590461)
1. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461 [TBL] [Abstract][Full Text] [Related]
2. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270 [TBL] [Abstract][Full Text] [Related]
3. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562 [TBL] [Abstract][Full Text] [Related]
4. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial. Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639 [TBL] [Abstract][Full Text] [Related]
5. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027 [TBL] [Abstract][Full Text] [Related]
6. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. Kebir S; Schaub C; Junold N; Hattingen E; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Galldiks N; Weller J; Mack F; Tzaridis T; Bähr O; Seidel C; Schlegel U; Schmidt-Graf F; Rohde V; Borchers C; Tabatabai G; Hänel M; Sabel M; Gerlach R; Krex D; Belka C; Vatter H; Proescholdt M; Glas M; Herrlinger U J Neurooncol; 2019 Sep; 144(3):501-509. PubMed ID: 31325144 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827 [TBL] [Abstract][Full Text] [Related]
8. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089 [TBL] [Abstract][Full Text] [Related]
9. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Blumenthal DT; Won M; Mehta MP; Gilbert MR; Brown PD; Bokstein F; Brachman DG; Werner-Wasik M; Hunter GK; Valeinis E; Hopkins K; Souhami L; Howard SP; Lieberman FS; Shrieve DC; Wendland MM; Robinson CG; Zhang P; Corn BW Neuro Oncol; 2018 Jun; 20(7):966-974. PubMed ID: 29462493 [TBL] [Abstract][Full Text] [Related]
10. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178 [TBL] [Abstract][Full Text] [Related]
11. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U Oncology; 2013; 85(3):191-5. PubMed ID: 24008924 [TBL] [Abstract][Full Text] [Related]